You are here

P&T® Journal contents for November 2005

Features

An expert panel suggests setting limits on recombinant human factor VII (rFVIIa, NovoSeven®) therapy for bleeding because of concerns about its safety, effectiveness, and cost.
Aryeh Shander, MD, Lawrence Tim Goodnough, MD, Thomas Ratko, PhD, Karl A. Matuszewski, MS, PharmD, Stephen Cohn, MD, Michael Diringer, MD, Henry Edmunds, MD, Jeffrey Lawson, MD, PhD, Robert MacLaren, PharmD, Paul Ness, MD, Roger Shere-Wolfe, MD, JD, and Robert Dubois, MD
Commentary
Ms. Pauli reflects on a paradigm shift that is taking place in drug development and patient care: from global treatment modalities to more individualized therapeutics based on genomic data.
Emily K. Pauli, BS, BMS, PharmD Candidate
The authors offer a preview of what will take place for “dual eligibles,” whose costs for prescription drugs were covered by both Medicaid and Medicare, as they are transferred from Medicaid to the new Medicare drug plans in 2006.
Richard Stefanacci, DO, MGH, MBA, AGSF, CMD, and Steven L. Phillips, MD, CMD
Dr. Goldenberg reviews exemestane (Aromasin®) for treating estrogen receptor–positive breast cancer; a vaccine (Proquad®) for protection against measles, mumps, rubella, and chickenpox in children; and a vaccine (Fluarix™) for immunization against influenza virus types A and B in adults.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Therapies for migraine, multiple sclerosis, Parkinson’s disease, diabetic peripheral neuropathy, agitation, Alzheimer’s disease, and other disorders are presented.
Lawrence M. Prescott, PhD, and Sharon L. Prescott

Departments

Editorial
David Nash, MD, MBA, discusses a new Web site called “Best Buy Drugs,” a project of Consumer Reports magazine.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, reviews some of the dangers of complacency on the job, especially when automation or technology is present.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas outlines the preparatory steps the government is taking, albeit slowly, to avoid an avian influenza pandemic.
Stephen Barlas
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
Drug Forecast
The authors review the benefits of abatacept (CTLA4-Ig, Orencia), an investigational compound for the treatment of rheumatoid arthritis.
Payam Parchamazad, PharmD Candidate, Patty Ghazvini, PharmD, Marlon Honeywell, PharmD, and Phillip Treadwell, PharmD